Fujifilm Biotechnologies said its Holly Springs, North Carolina cell culture facility was selected for the FDA’s PreCheck Pilot Program. The initiative is designed to improve early interaction between FDA and manufacturers to reduce uncertainty around manufacturing readiness and to enable more predictable facility inspection outcomes. Along with Fujifilm, the pilot includes only a small set of participants such as Amneal Pharmaceutical, Cellares, Eli Lilly, Kriya Therapeutics, Kyowa Kirin, and Regeneron. Fujifilm’s Holly Springs site manufactures monoclonal antibodies, including multiple complex biologics for customer portfolios, positioning it to support clients seeking faster pathways to clinical supply continuity.